Cristiano Ronaldo Takes Home Alipay Top Scorer Trophy at UEFA EURO 2020
Portuguese football star Cristiano Ronaldo today became the winner of the Gold Trophy of the Alipay Top Scorer Awards at UEFA EURO 2020. Regarded as one of the greatest footballers of all time, Ronaldo netted five goals and made one assist at the competition. Patrik Schick from the Czech Republic was awarded the Silver Trophy, scoring five goals, while France’s Karim Benzema was the recipient of the Bronze Trophy, netting four goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210711005035/en/
Portuguese football star Cristiano Ronaldo became the winner of the Gold Trophy of the Alipay Top Scorer Awards at UEFA EURO 2020. (Photo: Business Wire)
The Alipay Top Scorer trophies are the first major international football Top-Scorer trophies to embed blockchain in their design, incorporating a hash code at the base through which scoring records of the tournament’s top three scorers can be uploaded and permanently stored on a blockchain powered by AntChain. Using the hash code provided, Alipay will upload the trophy data to the blockchain, ensuring a permanent, immutable record of the top scorers’ achievements.
“Our warmest congratulations to Cristiano Ronaldo for his phenomenal performances at UEFA EURO 2020, and for winning the Alipay Top Scorer Gold Award,” said Eric Jing, Chairman and CEO of Ant Group, who presented the top scorer trophies via video from Hangzhou immediately after the final game of UEFA EURO 2020. “Just as we have used blockchain technology to permanently preserve the wonderful scoring moments of the top scorers like him, we will also keep working with UEFA, to explore innovative digital solutions that improve fans’ experiences while enjoying football.”
UEFA and AntChain, one of the technology brands of Ant Group, on June 10 announced a five-year global partnership to jointly explore using blockchain technology to accelerate the digital transformation of the football industry and improve the experiences of fans across the globe. Under the agreement, AntChain became the official global blockchain partner of UEFA EURO 2020.
To honor the performances of the top scoring players, an AntChain-developed digital record of highlights from the UEFA EURO 2020 top scorers will be preserved at UEFA’s headquarters, making it the first digital collectible in the history of the EURO Top Scorer.
“The top scoring moments digital collectible will serve as a lasting memento, encouraging football fans around the world to spread the team spirit and happiness that are part and parcel of this beloved sport,” said Mr. Jing.
The UEFA EURO 2020 Top Scorer trophies are designed by Alipay, the world’s leading digital payment and lifestyle platform operated by Ant Group, which has been UEFA’s global partner since November 2018.
On June 12, UEFA launched a new mini program with Alipay to improve engagement with mobile-savvy Chinese football fans. Dubbed the UEFA EURO 2020 Official Digital Hub, the mini program offers football fans across China an inside look at the tournament through regular news updates, interviews with key players, and much more. The UEFA mini program has rapidly become the most popular sports-focused mini program on Alipay, attracting over 12 million users as of July 11.
During the tournament, Alipay launched a campaign via the UEFA EURO 2020 Dream Tour mini program that enables authenticated users to earn points by engaging in various fan activities. Powered by AntChain's technologies, the top 1,600 users will receive gold, silver, and bronze digital trophies as a form of digital souvenir with certificates on a blockchain.
Alipay also launched "Top Scorers on Campus,” a new advocacy program dedicated to supporting the development of campus football in China. To inspire more teenagers to pursue their football dreams, the program will award trophies with the same design as the Alipay Top Scorer Gold Trophy of the UEFA EURO 2020 to the best young players in campus football tournaments across China. Similar to the UEFA EURO 2020 Top Scorer Trophy, these students’ scoring records and achievements will also be stored on a blockchain provided by AntChain.
About AntChain
AntChain is one of Ant Group’s technology brands. According to IPR Daily and patent database IncoPat, Ant Group held the highest number of published blockchain-related patent applications between 2017 and the six months ended June 30, 2020. Since the launch of Ant Group’s blockchain business in 2016, the company has pioneered the use of AntChain in over 50 blockchain commercial applications and use cases, including supply chain finance, cross-border remittance, charitable donations, and product provenance.
About Alipay
Alipay is the leading digital payment platform in China, serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.
Ant Group has further introduced Alipay+, the global cross-border mobile payments and marketing solution which enables merchants, especially small and medium-sized businesses, to better serve consumers from all over the world by collaborating with global partners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210711005035/en/
Contact information
For media enquiries
Ant Group
Vick Li Wei
Email: vick.lw@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom